CN1812792A - 双嘧达莫或单哌潘生丁用于治疗和预防凝血酶过量产生和/或凝血酶受体表达增加引起的血栓栓塞疾病和紊乱 - Google Patents

双嘧达莫或单哌潘生丁用于治疗和预防凝血酶过量产生和/或凝血酶受体表达增加引起的血栓栓塞疾病和紊乱 Download PDF

Info

Publication number
CN1812792A
CN1812792A CNA200480017862XA CN200480017862A CN1812792A CN 1812792 A CN1812792 A CN 1812792A CN A200480017862X A CNA200480017862X A CN A200480017862XA CN 200480017862 A CN200480017862 A CN 200480017862A CN 1812792 A CN1812792 A CN 1812792A
Authority
CN
China
Prior art keywords
thrombin
dipyridamole
disease
increased
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480017862XA
Other languages
English (en)
Chinese (zh)
Inventor
沃尔夫冈·艾塞特
维克托·L·塞里布鲁阿尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN1812792A publication Critical patent/CN1812792A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200480017862XA 2003-04-24 2004-04-17 双嘧达莫或单哌潘生丁用于治疗和预防凝血酶过量产生和/或凝血酶受体表达增加引起的血栓栓塞疾病和紊乱 Pending CN1812792A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46516803P 2003-04-24 2003-04-24
US60/465,168 2003-04-24

Publications (1)

Publication Number Publication Date
CN1812792A true CN1812792A (zh) 2006-08-02

Family

ID=33311001

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480017862XA Pending CN1812792A (zh) 2003-04-24 2004-04-17 双嘧达莫或单哌潘生丁用于治疗和预防凝血酶过量产生和/或凝血酶受体表达增加引起的血栓栓塞疾病和紊乱

Country Status (12)

Country Link
US (3) US20050014770A1 (https=)
EP (2) EP1622621A2 (https=)
JP (1) JP2006524203A (https=)
KR (1) KR20060007034A (https=)
CN (1) CN1812792A (https=)
AU (1) AU2004231306A1 (https=)
BR (1) BRPI0409796A (https=)
CA (1) CA2523157A1 (https=)
MX (1) MXPA05011432A (https=)
RU (1) RU2005136383A (https=)
WO (1) WO2004093881A2 (https=)
ZA (1) ZA200508016B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US20090048173A1 (en) 2004-05-13 2009-02-19 Wolfgang Eisert Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
WO2006045756A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005028168B3 (de) 2005-06-17 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Einrichtung zur Führung eines Gases für Vorrichtungen zum Behandeln körnigen Gutes durch Trocknen, Filmcoaten oder Beschichten, insbesondere Zulufteinheit und Vorrichtung mit einer derartigen Einrichtung
AR062057A1 (es) * 2006-07-17 2008-10-15 Boehringer Ingelheim Int Uso de los inhibidores directos de la trombina
CL2007002067A1 (es) * 2006-07-17 2008-01-25 Boehringer Ingelheim Int Uso de dabigatran etexilato, inhibidores directos de la trombina, para el tratamiento y/o profilaxis en niños de enfermedades tales como infarto cerebral no hemorragico, infarto de miocardio, arritmia, trombosis venosa central, entre otras.
CA2657266A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
RU2377990C1 (ru) * 2008-07-23 2010-01-10 Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов
CA2734809A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Dabigatran in tumour therapy
AR074108A1 (es) * 2008-11-11 2010-12-22 Boehringer Ingelheim Int Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina
US20130131088A1 (en) * 2010-01-13 2013-05-23 University Health Network Treating cancer with statins and compounds having dipyridamole activity
KR20180074707A (ko) * 2015-10-15 2018-07-03 모세 로고스니츠키 저 용량 경구 디피리다몰 조성물 및 이의 용도
WO2019241793A1 (en) * 2018-06-15 2019-12-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of detection of mechanically-activated platelet activation and uses thereof
US20260060965A1 (en) * 2024-08-26 2026-03-05 Research Institute at Nationwide Children’s Hospital Modulating the acute foreign body reaction to reduce stenosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
GB1051218A (https=) 1963-03-09
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DE3627423A1 (de) 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
DE4035961A1 (de) 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US20020048599A1 (en) 2000-10-20 2002-04-25 Thomas H. Mueller Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation
HUP0304058A2 (hu) * 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
EP1250921A1 (en) 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol
EP1308179A1 (en) * 2001-10-30 2003-05-07 Boehringer Ingelheim Pharma GmbH & Co.KG Improved endoprosthetic device
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
CA2496445A1 (en) * 2002-08-14 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
CN1747734A (zh) * 2003-02-07 2006-03-15 贝林格尔·英格海姆国际有限公司 潘生丁或单哌潘生丁在治疗和预防mmp－9－依赖性疾病中的用途

Also Published As

Publication number Publication date
RU2005136383A (ru) 2007-06-10
KR20060007034A (ko) 2006-01-23
ZA200508016B (en) 2007-03-28
WO2004093881A3 (en) 2005-06-16
US20070105753A1 (en) 2007-05-10
BRPI0409796A (pt) 2006-05-30
EP1622621A2 (en) 2006-02-08
MXPA05011432A (es) 2006-03-21
CA2523157A1 (en) 2004-11-04
JP2006524203A (ja) 2006-10-26
AU2004231306A1 (en) 2004-11-04
US20050014770A1 (en) 2005-01-20
EP2062580A1 (en) 2009-05-27
US20090192123A1 (en) 2009-07-30
WO2004093881A2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CN1812792A (zh) 双嘧达莫或单哌潘生丁用于治疗和预防凝血酶过量产生和/或凝血酶受体表达增加引起的血栓栓塞疾病和紊乱
CN107427522B (zh) 用于治疗黑素瘤的阿吡莫德
BR112015026418B1 (pt) Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
CN1823780A (zh) 潘生丁或单哌潘生丁在制备用于治疗及预防血纤维蛋白依赖性微循环障碍药物中的用途
JP2023075272A (ja) ガン治療
KR101563069B1 (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
US20050281868A1 (en) Transdermal delivery system for statin combination therapy
EP1973542A2 (en) Treatment of cachexia with statins
CN1747734A (zh) 潘生丁或单哌潘生丁在治疗和预防mmp－9－依赖性疾病中的用途
TW201834649A (zh) 癌症療法
JP2018150292A (ja) がん治療
WO2018222134A1 (en) Cancer therapy
Naik et al. Management of hypertension-journey from single drug therapy to multitargeted ligand therapy: a clinical overview
IL294399A (en) Combination therapy for treating cancer
WO2018222135A1 (en) Cancer therapy
JP2013510866A (ja) 組み合わせたチボザニブおよびテムシロリムス
EP3784243B1 (en) Methotrexate for use as a medicament
US20230029336A1 (en) Combination Therapy for Treating a Hematological Malignancy
WO2024102968A1 (en) Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
EP3976036A1 (en) Methods and uses for treating cancer
HK1261004A1 (en) Cancer therapy
Abdel-Aziz Current perspectives on sunitinib targeted therapy for tumors
TW200522965A (en) Novel pharmaceutical combination comprising pyrimido-pyrimidine in combination with one other active component for treatment and prevention of fibrin-dependent microcirculation disorders
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
JP2011225553A (ja) 手足症候群の予防および治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060802